

## RESEARCH ARTICLE

# Curcumin Induces Apoptosis in Pre-B Acute Lymphoblastic Leukemia Cell Lines Via PARP-1 Cleavage

Deepshikha Mishra<sup>1</sup>, Sunita Singh<sup>2</sup>, Gopeshwar Narayan<sup>1\*</sup>

### Abstract

Curcumin, a polyphenolic compound isolated from the rhizomes of an herbaceous perennial plant, *Curcuma longa*, is known to possess anticancerous activity. However, the mechanism of apoptosis induction in cancers differs. In this study, we have (1) investigated the anticancerous activity of curcumin on REH and RS4;11 leukemia cells and (2) studied the chemo-sensitizing potential of curcumin for doxorubicin, a drug presently used for leukemia treatment. It was found that curcumin induced a dose dependent decrease in cell viability because of apoptosis induction as visualized by annexin V-FITC/ PI staining. Curcumin-induced apoptosis of leukemia cells was mediated by PARP-1 cleavage. An increased level of caspase-3, apoptosis inducing factor (AIF), cleaved PARP-1 and decreased level of Bcl2 was observed in leukemia cells after 24h of curcumin treatment. In addition, curcumin at doses lower than the IC<sub>50</sub> value significantly enhanced doxorubicin induced cell death. Therefore, we conclude that curcumin induces apoptosis in leukemia cells via PARP-1 mediated caspase-3 dependent pathway and further may act as a potential chemo-sensitizing agent for doxorubicin. Our study highlights the chemo-preventive and chemo-sensitizing role of curcumin.

**Keywords:** Curcumin - leukemia - PARP-1 - REH - RS4;11

*Asian Pac J Cancer Prev*, 17 (8), 3865-3869

### Introduction

Natural phytochemicals, as supplements or alternative to some chemotherapeutic drugs, show synergistic effect and thereby result in decline in drug related toxicity. Curcumin (diferuloylmethane) is a yellow coloured polyphenol derived from the rhizome of perennial plant *Curcuma longa*, growing commonly in India. It is one of the extensively investigated compounds for its medicinal values in various diseases. Curcumin is known to possess a significant anti cancerous activity and is reported to induce apoptosis in different cancers like gastric carcinoma (Xue et al., 2014; Ji et al., 2014), skin squamous cell carcinoma (Wu et al., 2015), colon cancer (Dehghan et al., 2015), lung cancer (Badrzadeh et al., 2014; Xia et al., 2014), renal cell carcinoma (Pei et al., 2014), ovarian cancer (Zhao et al., 2014), liver cancer (Li et al., 2014; Dai et al., 2013) leukemia (Banjerdpongchai et al., 2005; Gopal et al., 2014) and cervical carcinoma (Basu et al., 2013) by multiple mechanisms like reactive oxygen species (ROS) generation, autophagy, activation of NF- $\kappa$ B pathway, mitochondrial membrane potential (MMP) dissipation with the release of cytochrome c in cytoplasm, down-regulation of anti-apoptotic marker Bcl-2, up-regulation of pro-apoptotic marker Bax and production of increased cleaved PARP. Apart from having protective effect on normal human cells, curcumin is

reported to effectively sensitize cancer cells to a broad range of chemotherapeutic drugs like bortezomib, doxorubicin, 5-FU, paclitaxel, celecoxib, vinorelbine, vincristine, butyrate, cisplatin, melphalan, gemcitabine, etoposide, oxaliplatin, sulfinosine, and thalidomide (Goel, 2010). It enhances apoptotic potential of drugs like etoposide through the generation of reactive oxygen species in myeloid leukemia cells (Papiez et al., 2016), imatinib through disrupting redox potential by generated reactive oxygen species in chronic myeloid leukemia cells (Acharya, 2016), Busulfan via downregulating survivin expression in KG1a cells having stem cell property (Weng et al., 2015), cytarabine via down regulating MDR genes in acute myeloid leukemia cells (Shah et al., 2015), bortezomib in leukemia cells and xenograft models (Nagy et al., 2015), arsenic trioxide via downregulating BCL-2 and PARP in leukemia cells (Wang et al., 2013), imatinib in acute leukemia via downregulating AKT/mTOR pathway (Guo et al., 2015), ATRA (all-trans retinoid acid) via activating PI3K/AKT pathway in acute promyelocytic leukemia cells (Chen et al., 2013), methotrexate via overexpression of folate receptor in leukemia cells (Dhanasekaran et al., 2013), valproic acid via p38-dependent pathway (Chen et al., 2010) and rapamycin via caspases dependent pathway (Hayun et al., 2009).

Leukemia is a heterogeneous disease affecting

<sup>1</sup>Department of Molecular and Human Genetics, <sup>2</sup>Department of Zoology, Mahila Mahavidyalaya, Banaras Hindu University, Varanasi, India \*For correspondence: gnarayan@bhu.ac.in

different types of blood cells. Acute lymphoblastic leukaemia, with prevalence in children of the age group 2 to 5 years, is a malignancy affecting lymphoid progenitor cells (Pui et al., 2008). Revolutionising advances in treatment regimens has resulted in achieving cure rate higher than 80% in children, however using innovative approaches to make chemotherapy more effective, would help in acquiring higher percentage of leukaemia-free survival and reduced treatment related toxic side-effects (Pui et al., 2004; Pui et al., 2006; Pui et al., 2008). Much is known about the anti cancerous role of curcumin, however the accurate mechanism underlying cell apoptosis in pre-B acute lymphoblastic leukemia is still unclear. In the present study, we have investigated anti leukemic effect of curcumin and associated apoptotic pathway. Further, we have also explored chemo-sensitizing role of curcumin and the underlying mechanism of apoptosis involved. We have attempted to define the chemotherapeutic and chemosensitizing potential of curcumin.

## Materials and Methods

### Cell culture and chemicals

Two pre-B acute lymphoblastic leukemia cell lines RS4;11 and REH were grown in RPMI-1640 medium (Gibco, Life Technologies, USA), supplemented with 10% heat-inactivated fetal bovine serum (Gibco, Life Technologies, USA), 1% antibiotics (Cellclone, Genetix Biotech Asia Pvt Ltd, India) in a 5% CO<sub>2</sub> incubator at 37°C. Curcumin (Sigma, St. Louis, MO, USA) and doxorubicin hydrochloride (Sigma, St. Louis, MO, USA) main stocks were prepared in pure dimethyl sulfoxide (DMSO) (Sigma, St. Louis, MO, USA). All chemicals used were of highest purity grade available. For MTT assay, EZcount MTT cell assay kit (Himedia, India) was purchased. Antibodies anti-Caspase-3, anti-poly-adenosine diphosphate ribose polymerase-1 (anti-PARP-1) and anti-Bcl2 (Cell Signalling Technology, MA, USA), anti-AIF (Santa Cruz Biotechnology, USA) and anti-GAPDH (Imgenex, India) antibodies were used for western blotting.

### Cell viability assay

Five thousand cells per well ( $5 \times 10^3$  cells/well) were seeded in 96-well plates. After 24h incubation, cells were treated dose dependently with 10 to 100µM curcumin for 24h or DMSO (control group) and 5nM doxorubicin hydrochloride. Cell cytotoxicity was assessed by MTT cell assay kit as per manufacturer's protocol. Yellow colored water soluble tetrazolium dye 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduced to formazan crystals was dissolved in DMSO. Absorbance was recorded at 570nm on a microplate reader (BioRad, USA). The percentage of cell viability was calculated using the formula: Cell viability (%) = OD of treated / OD of control  $\times 100$ .

### Cell cycle assay

To check the proportion of REH and RS;411 cells in different phases of cell cycle, the DNA content was detected by propidium iodide staining (Sigma, St. Louis,

MO, USA) by flow cytometry. Cells seeded in 6-well plates were grown for 24h without drug, after 24h both the cell lines were incubated with curcumin (10 and 20 µM) or DMSO (control) for 24h and then collected, centrifuged at 5000 RPM for 5 minutes. Pelleted cells were washed with PBS, and fixed with 70% ethanol. Again after centrifugation, cells were resuspended in PBS containing 0.1 mg/ml RNase A (Amresco, USA) and incubated for 2h at room temperature. Finally just before analysis 2 µg/ml propidium iodide was added and cell cycle distribution was determined by flow cytometry. Stained cell were read for DNA content by BD-FACS calibur instrument (BD-Biosciences, USA), analysis was done by CellQuest pro (BD-Biosciences, USA).

### Apoptosis assay

AnnexinV-FITC/ propidium iodide assay was performed to calculate apoptotic cells as per manufacturer's protocol (Invitrogen, Molecular Probes, USA). Cells were seeded in 5ml media in 6-well plates, cells at semi-confluent stage were treated with curcumin (10µM and 20µM) for 24h. Apoptotic events were acquired and analyzed by BD-FACS calibur instrument (BD-Biosciences, USA).

### Western blotting

Cells treated with curcumin alone or in combination with doxorubicin were collected after 24h treatment and washed twice with PBS. Cell lysis was done with ice-cold RIPA lysis buffer (Sigma Aldrich, USA). Cell lysate was kept on ice for 30 min followed by gentle vortexing in between, and then centrifugation was done at 12,000 rpm for 10 min at 4°C. The supernatant was collected and transferred in fresh microfuge tube and stored at -80°C for further use. Equal quantity of protein (50µg) was used for western blot analysis. Equal amounts of protein were loaded in each lane of 10% SDS-PAGE gel. Resolved protein was later electro-transferred onto PVDF membranes (Millipore, USA). PVDF membranes were blocked with 5% non-fat milk in TBST containing 0.5% Tween-20. After blocking, PVDF membranes were incubated with anti-PARP-1, anti-AIF, anti-Bcl2 and anti-GAPDH antibodies for overnight at 4°C. Membranes were further incubated with their respective secondary antibodies conjugated to ALP for 2h. After this membranes were exposed to BCIP/NBT solution (Amersco, USA).

### Chemo-sensitization

To study the effect of curcumin as a sensitizing agent to enhance the apoptotic potential of chemotherapeutic drug doxorubicin, cells were seeded in 5ml media in 6-well plates, after 24h incubation, cells at semi confluent stage were treated with curcumin (10µM) alone or doxorubicin (5nM) alone or combined dose of curcumin (10µM) with doxorubicin (2.5nM) and curcumin (10µM) with doxorubicin (5nM) for 24h.

## Results

### Curcumin decreases leukemia cell viability

Curcumin treatment resulted in cell death in leukemia


cell lines with a half maximal inhibitory concentration ( $IC_{50}$ ) ranging from  $10\mu\text{M}$  to  $20\mu\text{M}$ . Curcumin induced a dose-dependent decrease in cell viability after 24h treatment (Figure 1b and 1c) suggesting a cytotoxic role.

#### Curcumin arrests pre-B leukemia cells in G2-M phase and increases sub G1 population


To understand the effect of curcumin treatment on cell cycle distribution it was found that curcumin treatment arrested REH and RS4;11 cells in G2-M phase (Figure 2). Further, a significant increase in sub G1 population was also found after 24h curcumin treatment which signifies rise in apoptotic population.

#### Curcumin induces apoptosis in leukemia cell lines


To confirm the cell death by apoptosis, annexin V-FITC/PI staining was done on curcumin treated cells.



**Figure 1. a) Curcumin Structure; Curcumin Decreases b) REH and c) RS4;11 cell Viability when Treated with Varying Concentrations of Curcumin from  $10\mu\text{M}$  to  $100\mu\text{M}$ .  $IC_{50}$  was determined by MTT assay after 24h. Two-tailed student t-test was applied**



**Figure 2. Curcumin Induces G2-M arrest in both REH (Upper Panel) and RS4;11 (Lower Panel) Cells with a Increase in sub G1 Cell Population after 24h after  $10\mu\text{M}$  and  $20\mu\text{M}$  Curcumin Treatment**




**Figure 3. Curcumin Induces Apoptosis in REH (upper panel) and RS4;11 (Lower Panel) Cells Treated with Different Concentrations of Curcumin  $10\mu\text{M}$  and  $20\mu\text{M}$  for 24h, Followed by Annexin V/PI Staining**


Q2 quadrant (FITC+/PI+) stands for late apoptotic cells; Q3 quadrant (FITC-/PI-) shows live cells and Q4 quadrant (FITC+/PI-) represents early apoptotic cells. Flow cytometry results suggest a distinct dose-dependent increase in late apoptotic cells after curcumin treatment as compared to control cells (Figure 3). The annexin V-/PI-, annexin V+/PI-, and annexin V+/PI+ quadrants indicate the percentage cell population of normal cells, early apoptosis and late apoptosis respectively. Percentage of early apoptotic REH cells increased dose dependently from 0.27 in control to 0.79 and 2.94 subsequently. Percentage of cells in late apoptosis increased from 0.44 in control to 2.39 and 18.54 in REH cells. Similar pattern was observed in RS4;11 cells, early apoptotic cells increased from 0.36 in control to 0.60 and 0.86 dose dependently. Late apoptotic cells increased from 0.91 to 18.18 and 47.46 dose dependently. Total apoptotic cells (Q2 and Q4 quadrants) increased dose dependently in both cell lines after curcumin treatment.

#### Curcumin induces apoptosis by cleavage of PARP-1

PARP-1 is the downstream substrate of caspase family and is a hallmark mediator of the apoptosis. Curcumin treatment resulted in significant dose dependent increase in apoptotic cells as indicated from MTT and apoptosis assay in REH and RS4;11 cells, suggesting cell death via apoptotic pathway. This result was further confirmed by western blotting of PARP-1; dose dependent cleavage of full length PARP-1 was found after curcumin treatment. We validated apoptosis by doing western blotting for PARP-1 after 24h treatment. Curcumin cleaves PARP-1 forming 116 and 89kD bands suggesting caspase pathway mediated apoptosis after 24h treatment ( $10$  and  $20\mu\text{M}$ ) (Figure 4). PARP-1 cleavage thereby confirms apoptosis. Band densitometric analysis shows increased expression of full length caspase-3 and apoptosis inducing factor



**Figure 4. Curcumin Induces Apoptosis in REH and RS4;11 Cells Treated with  $10\mu\text{M}$  and  $20\mu\text{M}$  Curcumin for 24h through Caspase Dependent PARP-1 cleavage**



**Figure 5. Curcumin Induces Apoptosis in REH and RS4;11 cells treated with Alone and in Combination with Doxorubicin Hydrochloride for 24h, through PARP-1 cleavage**

(AIF) with a dose dependent down regulation of Bcl2 (Figure 4).

#### *Curcumin potentiates apoptosis induced by doxorubicin hydrochloride*

Doxorubicin is an age old chemotherapeutic drug known to induce apoptosis in various malignancies. IC<sub>50</sub> dose was calculated using MTT assay. IC<sub>50</sub> dose 5nM and a dose lower than IC<sub>50</sub> value 2.5nM was chosen. It was found that both 10µM curcumin and 5nM doxorubicin induced apoptosis as evident by PARP-1 cleavage. However, when given simultaneously, a 2.5nM doxorubicin and 10µM curcumin induced a higher level of apoptosis. With a gradual increase in 89kD fragment of PARP-1, increased level of apoptosis was also observed dose dependently which suggests enhanced level of apoptosis when curcumin was supplemented with doxorubicin in cell culture (Figure 5).

## Discussion

Multiple studies have shown chemotherapeutic role of curcumin on variety of tumor cells. Curcumin targets the genes involved in critical pathways of cancer including invasion, migration, and proliferation by inhibiting constitutively active NF-κB (Han et al., 2002), DNA damage to mitochondrial and nuclear genomes (Kong et al., 2009), inhibition of PI3K-AKT activation (Hussain et al., 2006), and regulating cell cycle (Park et al., 2002). In the present study, we evaluated the effect of curcumin on leukemia cell lines REH and RS4;11. Our experimental results showed that curcumin has chemotherapeutic potential as it dose dependently exhibited cytotoxicity to human pre-B acute lymphoblastic leukemia cells, with an IC<sub>50</sub> ranging in between 10 to 20µM. Annexin V-FITC/PI apoptosis assay suggested that percentage of total apoptotic cells increased after curcumin treatment. Our immunoblotting results validated the curcumin induced caspase-3 dependent PARP-1 mediated apoptosis in these leukemia cells. Further, this study also demonstrates that curcumin has the potential to chemo-sensitize cells for doxorubicin to work at dose lower than IC<sub>50</sub> value.

In conclusion, this study gives mechanistic insights about curcumin anti leukemia effect. Further it demonstrates that curcumin induces PARP-1 mediated cell apoptosis in leukemia cells and curcumin can behave as a potential sensitizing agent for doxorubicin, enhancing its apoptosis inducing potential.

## Acknowledgements

Junior and Senior research fellowships to DM from the Department of Biotechnology (DBT), Government of India is acknowledged. Authors acknowledge of Interdisciplinary School Life Sciences, Institute of Science for equipment facility.

## References

Acharya S, Sahoo SK (2016). Exploitation of redox discrepancy in leukemia cells by a reactive oxygen species nano scavenger for inducing cytotoxicity in imatinib resistant

cells. *J Colloid Interface Sci*, **467**, 180-91.

- Badrzadeh F, Akbarzadeh A, Zarghami N (2014). Comparison between effects of free curcumin and curcumin loaded NIPAAm-MAA nanoparticles on telomerase and PinX1 gene expression in lung cancer cells. *Asian Pac J Cancer Prev*, **15**, 8931-6.
- Banjerdpongchai R, Wilairat P (2005). Effects of water-soluble antioxidants and MAPKK/MEK inhibitor on curcumin-induced apoptosis in HL-60 human leukemic cells. *Asian Pac J Cancer Prev*, **6**, 282-5.
- Basu P, Dutta S, Begum R, et al (2013). Clearance of cervical human papillomavirus infection by topical application of curcumin and curcumin containing polyherbal cream: a phase II randomized controlled study. *Asian Pac J Cancer Prev*, **14**, 5753-9.
- Chen J, Wang G, Wang L, et al (2010). Curcumin p38-dependently enhances the anticancer activity of valproic acid in human leukemia cells. *Eur J Pharm Sci*, **41**, 210-8.
- Chen TY, Xu F, Kong YY, et al (2013). Effect of curcumin combined with ATRA on differentiation of ATRA-resistant acute promyelocytic leukemia cells. *Zhongguo Shi Yan Xue Ye Xue Za Zhi*, **21**, 895-8.
- Dai XZ, Yin HT, Sun LF, et al (2013). Potential therapeutic efficacy of curcumin in liver cancer. *Asian Pac J Cancer Prev*, **14**, 3855-9.
- Dehghan Esmatabadi MJ, Farhangi B, Safari Z, et al (2015). Dendrosomal curcumin inhibits metastatic potential of human SW480 colon cancer cells through Down-regulation of Claudin1, Zeb1 and Hef1-1 gene expression. *Asian Pac J Cancer Prev*, **16**, 2473-81.
- Dhanasekaran S, Biswal BK, Sumantran VN, et al (2013). Augmented sensitivity to methotrexate by curcumin induced overexpression of folate receptor in KG-1 cells. *Biochimie*, **95**, 1567-73.
- Fan JX, Zeng YJ, Wu JW, et al (2014). Synergistic killing effect of arsenic trioxide combined with curcumin on KG1a cells. *Zhongguo Shi Yan Xue Ye Xue Za Zhi*, **22**, 1267-72.
- Goel A, Aggarwal BB. (2010). Curcumin, the golden spice from Indian saffron, is a chemosensitizer and radiosensitizer for tumors and chemoprotector and radioprotector for normal organs. *Nutr Cancer*, **62**, 919-30.
- Gopal PK, Paul M, Paul S (2014). Curcumin induces caspase mediated apoptosis in JURKAT cells by disrupting the redox balance. *Asian Pac J Cancer Prev*, **15**, 93-100.
- Guo Y, Li Y, Shan Q, et al (2015). Curcumin potentiates the anti-leukemia effects of imatinib by downregulation of the AKT/mTOR pathway and BCR/ABL gene expression in Ph+ acute lymphoblastic leukemia. *Int J Biochem Cell Biol*, **65**, 1-11.
- Han SS, Keum YS, Seo HJ, et al (2002). Curcumin suppresses activation of NF-kappaB and AP-1 induced by phorbol ester in cultured human promyelocytic leukemia cells. *J Biochem Mol Biol*. **35**, 337-42
- Hayun R, Okun E, Berrebi A, et al (2009). Rapamycin and curcumin induce apoptosis in primary resting B chronic lymphocytic leukemia cells. *Leuk Lymphoma*, **50**, 625-32.
- Hussain AR, Al-Rasheed M, Manogaran PS, et al (2006). Curcumin induces apoptosis via inhibition of PI3'-kinase/AKT pathway in acute T cell leukemias. *Apoptosis*, **11**, 245-54.
- Ji J, Wang HS, Gao YY, et al (2014). Synergistic anti-tumor effect of KLF4 and curcumin in human gastric carcinoma cell line. *Asian Pac J Cancer Prev*, **15**, 7747-52.
- Kong Y, Ma W, Liu X, et al (2009). Cytotoxic activity of curcumin towards CCRF-CEM leukemia cells and its effect on DNA damage. *Molecules*, **14**, 5328-38.
- Li PM, Li YL, Liu B, et al (2014). Curcumin inhibits MHCC97H liver cancer cells by activating ROS/TLR-4/caspase

- signaling pathway. *Asian Pac J Cancer Prev*, **15**, 2329-34.
- Meiyanto E, Putri DD, Susidarti RA, et al (2014). Curcumin and its analogues (PGV-0 and PGV-1). enhance sensitivity of resistant MCF-7 cells to doxorubicin through inhibition of HER2 and NF- $\kappa$ B activation. *Asian Pac J Cancer Prev*, **15**, 179-84.
- Nagy LI, Feher LZ, Szebeni GJ, et al (2015). Curcumin and its analogue induce apoptosis in leukemia cells and have additive effects with bortezomib in cellular and xenograft models. *Biomed Res Int*. 968-81.
- Papiez MA, Krzysciak W, Szade K, et al (2016). Curcumin enhances the cytogenotoxic effect of etoposide in leukemia cells through induction of reactive oxygen species. *Drug Des Devel Ther*, **10**, 557-70.
- Park MJ, Kim EH, Park IC, et al (2002). Curcumin inhibits cell cycle progression of immortalized human umbilical vein endothelial (ECV304). cells by up-regulating cyclin-dependent kinase inhibitor, p21WAF1/CIP1, p27KIP1 and p53. *Int J Oncol*, **21**, 379-83
- Pei CS, Wu HY, Fan FT, et al (2014). Influence of curcumin on HOTAIR-mediated migration of human renal cell carcinoma cells. *Asian Pac J Cancer Prev*, **15**, 4239-43.
- Pui CH, Evans WE (2006). Treatment of acute lymphoblastic leukemia. *N Engl J Med*, **354**, 166-78.
- Pui CH, Relling MV, Downing JR (2004). Acute lymphoblastic leukemia. *N Engl J Med*, **350**, 1535-48.
- Pui CH, Robison LL, Look AT (2008). Acute lymphoblastic leukaemia. *Lancet*, **371**, 1030-43.
- Shah K, Mirza S, Desai U, et al (2015). Synergism of Curcumin and Cytarabine in the Down Regulation of Multi-Drug Resistance Genes in Acute Myeloid Leukemia. *Anticancer Agents Med Chem*, **16**, 128-35.
- Wang R, Xia L, Gabrilove J, et al (2013). Downregulation of Mcl-1 through GSK-3 $\beta$  activation contributes to arsenic trioxide-induced apoptosis in acute myeloid leukemia cells. *Leukemia*, **27**, 315-24.
- Wu J, Lu WY, Cui LL (2015). Inhibitory effect of curcumin on invasion of skin squamous cell carcinoma A431 cells. *Asian Pac J Cancer Prev*, **16**, 2813-8.
- Xia YQ, Wei XY, Li WL, et al (2014). Curcumin analogue A501 induces G2/M arrest and apoptosis in non-small cell lung cancer cells. *Asian Pac J Cancer Prev*, **15**, 6893-8.
- Xue X, Yu JL, Sun DQ, et al (2014). Curcumin induces apoptosis in SGC-7901 gastric adenocarcinoma cells via regulation of mitochondrial signaling pathways. *Asian Pac J Cancer Prev*, **15**, 3987-92.
- Zhao SF, Zhang X, Zhang XJ, et al (2014). Induction of microRNA-9 mediates cytotoxicity of curcumin against SKOV3 ovarian cancer cells. *Asian Pac J Cancer Prev*, **15**, 3363-8.